- Home
- PHIO vs SILO Comparison
PHIO vs SILO Comparison
Compare PHIO & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- SILO
- Stock Information
- Founded
- PHIO 2011
- SILO 2010
- Country
- PHIO United States
- SILO United States
- Employees
- PHIO N/A
- SILO N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- PHIO Health Care
- SILO Consumer Discretionary
- Exchange
- PHIO Nasdaq
- SILO Nasdaq
- Market Cap
- PHIO 8.6M
- SILO 3.1M
- IPO Year
- PHIO N/A
- SILO N/A
- Fundamental
- Price
- PHIO $2.00
- SILO $0.44
- Analyst Decision
- PHIO Strong Buy
- SILO
- Analyst Count
- PHIO 1
- SILO 0
- Target Price
- PHIO $4.00
- SILO N/A
- AVG Volume (30 Days)
- PHIO 875.3K
- SILO 639.0K
- Earning Date
- PHIO 05-15-2025
- SILO 05-09-2025
- Dividend Yield
- PHIO N/A
- SILO N/A
- EPS Growth
- PHIO N/A
- SILO N/A
- EPS
- PHIO N/A
- SILO N/A
- Revenue
- PHIO N/A
- SILO $72,102.00
- Revenue This Year
- PHIO N/A
- SILO $1.86
- Revenue Next Year
- PHIO N/A
- SILO N/A
- P/E Ratio
- PHIO N/A
- SILO N/A
- Revenue Growth
- PHIO N/A
- SILO N/A
- 52 Week Low
- PHIO $0.97
- SILO $0.41
- 52 Week High
- PHIO $9.79
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- PHIO 54.98
- SILO 31.78
- Support Level
- PHIO $1.71
- SILO $0.41
- Resistance Level
- PHIO $2.08
- SILO $0.49
- Average True Range (ATR)
- PHIO 0.13
- SILO 0.08
- MACD
- PHIO 0.01
- SILO -0.01
- Stochastic Oscillator
- PHIO 76.32
- SILO 4.78
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.